# Usana Health Sciences Inc: financial statements, quarterly

USNA · NYSE · CIK 896264 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jan 3

Pages: [Overview](/companies/usna.md) · [Financials](/companies/usna/financials.md) · [Filings](/companies/usna/filings.md) · [Insiders](/companies/usna/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/usna/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q4 FY2025 (2026-01-03) | Q1 FY2026 (2026-04-04) | Q2 FY2026 (2026-07-04) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [213](/filings/0000896264-24-000222.md) | [221 d](/filings/0000896264-26-000021.md) | [228](/filings/0000896264-25-000126.md) | [213](/filings/0000896264-25-000205.md) | [200](/filings/0000896264-25-000224.md) | [214 d](/filings/0000896264-26-000021.md) | [250](/filings/0000896264-26-000034.md) | [236](/filings/0000896264-26-000056.md) | [214](/filings/0000896264-25-000224.md) | [226 d](/filings/0000896264-26-000021.md) | [250](/filings/0000896264-26-000034.md) | [223](/filings/0000896264-26-000056.md) |
| Cost of revenue | $m | [42.5](/filings/0000896264-24-000222.md) | [42.3 d](/filings/0000896264-26-000021.md) | [43.1](/filings/0000896264-25-000126.md) | [40.3](/filings/0000896264-25-000205.md) | [39.3](/filings/0000896264-25-000224.md) | [38.6 d](/filings/0000896264-26-000021.md) | [52.4](/filings/0000896264-26-000034.md) | [50.2](/filings/0000896264-26-000056.md) | [48.8](/filings/0000896264-25-000224.md) | [49.4 d](/filings/0000896264-26-000021.md) | [59.4](/filings/0000896264-26-000034.md) | [48.3](/filings/0000896264-26-000056.md) |
| Gross profit | $m | [171](/filings/0000896264-24-000222.md) | [179 d](/filings/0000896264-26-000021.md) | [185](/filings/0000896264-25-000126.md) | [173](/filings/0000896264-25-000205.md) | [161](/filings/0000896264-25-000224.md) | [175 d](/filings/0000896264-26-000021.md) | [197](/filings/0000896264-26-000034.md) | [186](/filings/0000896264-26-000056.md) | [165](/filings/0000896264-25-000224.md) | [177 d](/filings/0000896264-26-000021.md) | [191](/filings/0000896264-26-000034.md) | [175](/filings/0000896264-26-000056.md) |
| Selling, general and administrative | $m | [63.3](/filings/0000896264-24-000222.md) | [58.7 d](/filings/0000896264-26-000021.md) | [64.3](/filings/0000896264-25-000126.md) | [64.3](/filings/0000896264-25-000205.md) | [61.3](/filings/0000896264-25-000224.md) | [73.3 d](/filings/0000896264-26-000021.md) | [91.4](/filings/0000896264-26-000034.md) | [81.9](/filings/0000896264-26-000056.md) | [85.9](/filings/0000896264-25-000224.md) | [78.1 d](/filings/0000896264-26-000021.md) | [88.3](/filings/0000896264-26-000034.md) | [82.3](/filings/0000896264-26-000056.md) |
| Operating income | $m | [17.6](/filings/0000896264-24-000222.md) | [24.2 d](/filings/0000896264-26-000021.md) | [24.7](/filings/0000896264-25-000126.md) | [17.8](/filings/0000896264-25-000205.md) | [15.6](/filings/0000896264-25-000224.md) | [8.2 d](/filings/0000896264-26-000021.md) | [15.7](/filings/0000896264-26-000034.md) | [16.7](/filings/0000896264-26-000056.md) | [1.2](/filings/0000896264-25-000224.md) | [3.8 d](/filings/0000896264-26-000021.md) | [13.9](/filings/0000896264-26-000034.md) | [(20.0)](/filings/0000896264-26-000056.md) |
| Interest expense | $m | [0.0](/filings/0000896264-23-000030.md) | [0.1 d](/filings/0000896264-24-000093.md) | [0.1](/filings/0000896264-24-000165.md) | [0.1](/filings/0000896264-25-000205.md) | [0.0](/filings/0000896264-25-000224.md) | [0.1 d](/filings/0000896264-26-000021.md) | [0.4](/filings/0000896264-26-000034.md) | [0.3](/filings/0000896264-26-000056.md) | [0.0](/filings/0000896264-25-000224.md) | [0.1 d](/filings/0000896264-26-000021.md) | [0.2](/filings/0000896264-26-000034.md) | [0.0](/filings/0000896264-26-000056.md) |
| Income tax | $m | [9.2](/filings/0000896264-24-000222.md) | [9.8 d](/filings/0000896264-26-000021.md) | [10.6](/filings/0000896264-25-000126.md) | [9.8](/filings/0000896264-25-000205.md) | [8.0](/filings/0000896264-25-000224.md) | [5.9 d](/filings/0000896264-26-000021.md) | [7.4](/filings/0000896264-26-000034.md) | [8.4](/filings/0000896264-26-000056.md) | [8.5](/filings/0000896264-25-000224.md) | [5.8 d](/filings/0000896264-26-000021.md) | [8.5](/filings/0000896264-26-000034.md) | [9.1](/filings/0000896264-26-000056.md) |
| Net income | $m | [11.3](/filings/0000896264-24-000222.md) | [16.8 d](/filings/0000896264-26-000021.md) | [16.5](/filings/0000896264-25-000126.md) | [10.4](/filings/0000896264-25-000205.md) | [10.6](/filings/0000896264-25-000224.md) | [4.5 d](/filings/0000896264-26-000021.md) | [9.4](/filings/0000896264-26-000034.md) | [9.7](/filings/0000896264-26-000056.md) | [(6.5)](/filings/0000896264-25-000224.md) | [(1.8) d](/filings/0000896264-26-000021.md) | [7.5](/filings/0000896264-26-000034.md) | [(21.4)](/filings/0000896264-26-000056.md) |
| Diluted EPS | $ per share | [0.59](/filings/0000896264-24-000222.md) | not reported | [0.86](/filings/0000896264-25-000126.md) | [0.54](/filings/0000896264-25-000205.md) | [0.56](/filings/0000896264-25-000224.md) | not reported | [0.49](/filings/0000896264-26-000034.md) | [0.52](/filings/0000896264-26-000056.md) | [(0.36)](/filings/0000896264-25-000224.md) | not reported | [0.41](/filings/0000896264-26-000034.md) | [(1.16)](/filings/0000896264-26-000056.md) |
| Basic EPS | $ per share | [0.59](/filings/0000896264-24-000222.md) | not reported | [0.86](/filings/0000896264-25-000126.md) | [0.55](/filings/0000896264-25-000205.md) | [0.56](/filings/0000896264-25-000224.md) | not reported | [0.49](/filings/0000896264-26-000034.md) | [0.52](/filings/0000896264-26-000056.md) | [(0.36)](/filings/0000896264-25-000224.md) | not reported | [0.41](/filings/0000896264-26-000034.md) | [(1.16)](/filings/0000896264-26-000056.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | FY2024 (2024-12-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | FY2025 (2026-01-03) | Q1 FY2026 (2026-04-04) | Q2 FY2026 (2026-07-04) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [307](/filings/0000896264-24-000222.md) | [330](/filings/0000896264-26-000021.md) | [328](/filings/0000896264-25-000126.md) | [332](/filings/0000896264-25-000205.md) | [365](/filings/0000896264-25-000224.md) | [182](/filings/0000896264-26-000021.md) | [180](/filings/0000896264-26-000034.md) | [151](/filings/0000896264-26-000056.md) | [145](/filings/0000896264-25-000224.md) | [158](/filings/0000896264-26-000056.md) | [163](/filings/0000896264-26-000034.md) | [169](/filings/0000896264-26-000056.md) |
| Current assets | $m | [390](/filings/0000896264-23-000030.md) | [418](/filings/0000896264-25-000092.md) | [421](/filings/0000896264-24-000165.md) | [419](/filings/0000896264-24-000208.md) | [451](/filings/0000896264-24-000222.md) | [279](/filings/0000896264-26-000021.md) | [281](/filings/0000896264-25-000126.md) | [262](/filings/0000896264-25-000205.md) | [264](/filings/0000896264-25-000224.md) | [288](/filings/0000896264-26-000056.md) | [294](/filings/0000896264-26-000034.md) | [281](/filings/0000896264-26-000056.md) |
| Total assets | $m | [601](/filings/0000896264-23-000030.md) | [633](/filings/0000896264-25-000092.md) | [629](/filings/0000896264-24-000165.md) | [631](/filings/0000896264-24-000208.md) | [671](/filings/0000896264-24-000222.md) | [748](/filings/0000896264-26-000021.md) | [747](/filings/0000896264-25-000126.md) | [735](/filings/0000896264-25-000205.md) | [727](/filings/0000896264-25-000224.md) | [743](/filings/0000896264-26-000056.md) | [739](/filings/0000896264-26-000034.md) | [703](/filings/0000896264-26-000056.md) |
| Current liabilities | $m | [113](/filings/0000896264-23-000030.md) | [119](/filings/0000896264-25-000092.md) | [113](/filings/0000896264-24-000165.md) | [104](/filings/0000896264-24-000208.md) | [115](/filings/0000896264-24-000222.md) | [140](/filings/0000896264-26-000021.md) | [137](/filings/0000896264-25-000126.md) | [122](/filings/0000896264-25-000205.md) | [119](/filings/0000896264-25-000224.md) | [129](/filings/0000896264-26-000056.md) | [117](/filings/0000896264-26-000034.md) | [106](/filings/0000896264-26-000056.md) |
| Total liabilities | $m | not reported | [136](/filings/0000896264-25-000092.md) | not reported | not reported | not reported | [162](/filings/0000896264-26-000021.md) | [163](/filings/0000896264-25-000126.md) | [149](/filings/0000896264-25-000205.md) | [145](/filings/0000896264-25-000224.md) | [157](/filings/0000896264-26-000056.md) | [144](/filings/0000896264-26-000034.md) | [132](/filings/0000896264-26-000056.md) |
| Shareholders' equity | $m | [470](/filings/0000896264-24-000222.md) | [497](/filings/0000896264-26-000021.md) | [500](/filings/0000896264-25-000205.md) | [512](/filings/0000896264-25-000224.md) | [533](/filings/0000896264-25-000224.md) | [532](/filings/0000896264-26-000056.md) | [530](/filings/0000896264-26-000056.md) | [531](/filings/0000896264-26-000056.md) | [528](/filings/0000896264-25-000224.md) | [533](/filings/0000896264-26-000056.md) | [544](/filings/0000896264-26-000056.md) | [526](/filings/0000896264-26-000056.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q4 FY2025 (2026-01-03) | Q1 FY2026 (2026-04-04) | Q2 FY2026 (2026-07-04) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [22.2 d](/filings/0000896264-24-000222.md) | [26.0 d](/filings/0000896264-26-000021.md) | [17.7](/filings/0000896264-25-000126.md) | [8.0 d](/filings/0000896264-25-000205.md) | [29.5 d](/filings/0000896264-25-000224.md) | [5.8 d](/filings/0000896264-26-000021.md) | [15.5](/filings/0000896264-26-000034.md) | [12.2 d](/filings/0000896264-26-000056.md) | [(2.0) d](/filings/0000896264-25-000224.md) | [(3.4) d](/filings/0000896264-26-000021.md) | [9.8](/filings/0000896264-26-000034.md) | [23.3 d](/filings/0000896264-26-000056.md) |
| Capital expenditure | $m | [1.5 d](/filings/0000896264-24-000222.md) | [7.3 d](/filings/0000896264-26-000021.md) | [3.2](/filings/0000896264-25-000126.md) | [2.7 d](/filings/0000896264-25-000205.md) | [2.4 d](/filings/0000896264-25-000224.md) | [1.8 d](/filings/0000896264-26-000021.md) | [2.8](/filings/0000896264-26-000034.md) | [5.0 d](/filings/0000896264-26-000056.md) | [3.2 d](/filings/0000896264-25-000224.md) | [2.8 d](/filings/0000896264-26-000021.md) | [2.6](/filings/0000896264-26-000034.md) | [3.2 d](/filings/0000896264-26-000056.md) |
| Share repurchases | $m | [11.6 d](/filings/0000896264-24-000222.md) | [0.0 d](/filings/0000896264-26-000021.md) | [9.4](/filings/0000896264-25-000126.md) | [0.0 d](/filings/0000896264-25-000205.md) | [0.0 d](/filings/0000896264-25-000224.md) | [0.0 d](/filings/0000896264-26-000021.md) | [12.3](/filings/0000896264-26-000034.md) | [15.2 d](/filings/0000896264-26-000056.md) | [0.0 d](/filings/0000896264-25-000224.md) | [0.0 d](/filings/0000896264-26-000021.md) | [0.0](/filings/0000896264-26-000034.md) | [0.0 d](/filings/0000896264-26-000056.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-10-01) | Q1 FY2023 (2023-04-01) | Q2 FY2023 (2023-07-01) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q1 FY2026 (2026-04-04) | Q2 FY2026 (2026-07-04) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [19.3](/filings/0000896264-23-000030.md) | [19.3](/filings/0000896264-24-000165.md) | [19.4](/filings/0000896264-24-000208.md) | [19.4](/filings/0000896264-24-000222.md) | [19.3](/filings/0000896264-25-000126.md) | [19.2](/filings/0000896264-25-000205.md) | [19.1](/filings/0000896264-25-000224.md) | [19.1](/filings/0000896264-26-000034.md) | [18.5](/filings/0000896264-26-000056.md) | [18.3](/filings/0000896264-25-000224.md) | [18.4](/filings/0000896264-26-000034.md) | [18.5](/filings/0000896264-26-000056.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 18,476,534 at 2026-08-11, from the cover of the [10-Q filed 2026-08-13](/filings/0000896264-26-000056.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:27 ET. No prices; not investment advice.